Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Genolimzumab - Apollomics

Drug Profile

Genolimzumab - Apollomics

Alternative Names: APL-501; CBT 501; GB 226; Recombinant humanised anti-PD-1 monoclonal antibody

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CBT Pharmaceuticals
  • Developer Apollomics; Genor Biopharma; Hutchison MediPharma
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alveolar soft part sarcoma; Cervical cancer; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Liver cancer
  • Phase I Colorectal cancer; Lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jul 2019 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT03976856)
  • 23 May 2019 Phase-II clinical trials in Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT03808857)
  • 04 Apr 2019 Phase-I clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT03977090)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top